Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:50:27.130Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:50:27.130Z.
Quote observation: 2026-10-06T15:49:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
Apnimed, Inc.
Market Cap
$804.23M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Apnimed, Inc. (APMD) | $804.23M | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 10.81 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $807.84M | N/A |
| AdaptHealth Corp. (AHCO)vs › | $796.23M | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $796.09M | N/A |
| Ardelyx, Inc. (ARDX)vs › | $816.21M | N/A |
| Geron Corporation (GERN)vs › | $789.71M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $788.45M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $778.78M | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $776.26M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
